Atomoxetine prevents dexamethasone-induced skeletal muscle atrophy in mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 3, 2014, Pages 663-673

  Jesinkey, Sean R ^a   Korrapati, Midhun C ^a   Rasbach, Kyle A ^a   Beeson, Craig C ^a   Schnellmann, Rick G ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; ATP SYNTHASE BETA; CYTOCHROME C OXIDASE; CYTOCHROME C OXIDASE SUBUNIT 1; FORMOTEROL FUMARATE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MYOSTATIN; NADH DEHYDROGENASE (UBIQUINONE) 1BETA SUBCOMPLEX 8; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN S6; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); RING FINGER PROTEIN; RING FINGER PROTEIN 1; SOMATOMEDIN C; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG; DEXAMETHASONE; PROPYLAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATP SYNTHASE BETA GENE; CONTROLLED STUDY; CYTOCHROME C OXIDASE SUBUNIT 1 GENE; DRUG EFFICACY; DRUG MECHANISM; FOXO3A GENE; GASTROCNEMIUS MUSCLE; GENE EXPRESSION; INSULIN LIKE GROWTH FACTOR 1 GENE; MALE; MAMMALIAN TARGET OF RAPAMYCIN GENE; MOUSE; MUSCLE ATROPHY; MUSCLE MASS; MYOSTATIN GENE; ND1 GENE; NONHUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RIBOSOMAL PROTEIN S6 GENE; RING FINGER PROTEIN 1 GENE; SIGNAL TRANSDUCTION; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; MUSCULAR ATROPHY; PATHOLOGY; SKELETAL MUSCLE;

ANIMALS; ATOMOXETINE HYDROCHLORIDE; DEXAMETHASONE; MALE; MICE; MICE, INBRED C57BL; MUSCLE, SKELETAL; MUSCULAR ATROPHY; PROPYLAMINES;

EID: 84930955617     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.114.217380     Document Type: Article

References (43)

1. Adams GR (2002a) Autocrine and/or paracrine insulin-like growth factor-I activity in skeletal muscle. Clin Orthop Relat Res (403, Suppl)S188-S196.
2. Adams GR (2002b) Invited Review: Autocrine/paracrine IGF-I and skeletal muscle adaptation. J Appl Physiol (1985) 93:1159-1167.
3. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, and Dharmarajan K, et al. (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294:1704-1708.
4. Bonaldo P and Sandri M (2013) Cellular and molecular mechanisms of muscle atrophy. Dis Model Mech 6:25-39.
5. Brault JJ, Jespersen JG, and Goldberg AL (2010) Peroxisome proliferator-activated receptor gamma coactivator 1alpha or 1beta overexpression inhibits muscle protein degradation, induction of ubiquitin ligases, and disuse atrophy. J Biol Chem 285:19460-19471.
6. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, and Perry KW (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711.
7. Carbó N, López-Soriano J, Tarragó T, González O, Llovera M, López-Soriano FJ, and Argilés JM (1997) Comparative effects of beta2-adrenergic agonists on muscle waste associated with tumour growth. Cancer Lett 115:113-118.
8. Fanzani A, Conraads VM, Penna F, and Martinet W (2012) Molecular and cellular mechanisms of skeletal muscle atrophy: an update. J Cachexia Sarcopenia Muscle 3:163-179.
9. Flück M (2006) Functional, structural and molecular plasticity of mammalian skeletal muscle in response to exercise stimuli. J Exp Biol 209:2239-2248.
10. Gomes MD, Lecker SH, Jagoe RT, Navon A, and Goldberg AL (2001) Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA 98:14440-14445.
11. He WA, Berardi E, Cardillo VM, Acharyya S, Aulino P, Thomas-Ahner J, Wang J, Bloomston M, Muscarella P, and Nau P, et al. (2013) NF-κB-mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexia. J Clin Invest 123:4821-4835.
12. Joassard OR, Amirouche A, Gallot YS, Desgeorges MM, Castells J, Durieux AC, Berthon P, and Freyssenet DG (2013a) Regulation of Akt-mTOR, ubiquitin-proteasome and autophagy-lysosome pathways in response to formoterol administration in rat skeletal muscle. Int J Biochem Cell Biol 45:2444-2455.
13. Joassard OR, Durieux AC, and Freyssenet DG (2013b) β2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders. Int J Biochem Cell Biol 45:2309-2321.
14. Kline WO, Panaro FJ, Yang H, and Bodine SC (2007) Rapamycin inhibits the growth and muscle-sparing effects of clenbuterol. J Appl Physiol (1985) 102:740-747.
15. Koopman R, Gehrig SM, Léger B, Trieu J, Walrand S, Murphy KT, and Lynch GS (2010) Cellular mechanisms underlying temporal changes in skeletal muscle protein synthesis and breakdown during chronic beta-adrenoceptor stimulation in mice. J Physiol 588:4811-4823.
16. Lee SJ (2004) Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol 20:61-86.
17. McPherron AC, Lawler AM, and Lee SJ (1997) Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 387:83-90.
18. Metter EJ, Talbot LA, Schrager M, and Conwit R (2002) Skeletal muscle strength as a predictor of all-cause mortality in healthy men. J Gerontol A Biol Sci Med Sci 57:B359-B365.
19. Mirbolooki MR, Constantinescu CC, Pan ML, and Mukherjee J (2013) Targeting presynaptic norepinephrine transporter in brown adipose tissue: a novel imaging approach and potential treatment for diabetes and obesity. Synapse 67:79-93.
20. Mootha VK, Handschin C, Arlow D, Xie X, St Pierre J, Sihag S, Yang W, Altshuler D, Puigserver P, and Patterson N, et al. (2004) Erralpha and Gabpa/b specify PGC-1alpha-dependent oxidative phosphorylation gene expression that is altered in diabetic muscle. Proc Natl Acad Sci USA 101:6570-6575.
21. Musarò A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, Barton ER, Sweeney HL, and Rosenthal N (2001) Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet 27:195-200.
22. Pearen MA, Myers SA, Raichur S, Ryall JG, Lynch GS, and Muscat GE (2008) The orphan nuclear receptor, NOR-1, a target of beta-adrenergic signaling, regulates gene expression that controls oxidative metabolism in skeletal muscle. Endocrinology 149:2853-2865.
23. Pearen MA, Ryall JG, Lynch GS, and Muscat GE (2009) Expression profiling of skeletal muscle following acute and chronic beta2-adrenergic stimulation: implications for hypertrophy, metabolism and circadian rhythm. BMC Genomics 10:448.
24. Peterson YK, Cameron RB, Wills LP, Trager RE, Lindsey CC, Beeson CC, and Schnellmann RG (2013) β2-Adrenoceptor agonists in the regulation of mitochondrial biogenesis. Bioorg Med Chem Lett 23:5376-5381.
25. Pocock SJ, McMurray JJ, Dobson J, Yusuf S, Granger CB, Michelson EL, Ostergren J, Pfeffer MA, Solomon SD, and Anker SD, et al. (2008) Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J 29:2641-2650.
26. Qin W, Pan J, Wu Y, Bauman WA, and Cardozo C (2010) Protection against dexamethasone-induced muscle atrophy is related to modulation by testosterone of FOXO1 and PGC-1α. Biochem Biophys Res Commun 403:473-478.
27. Ruas JL, White JP, Rao RR, Kleiner S, Brannan KT, Harrison BC, Greene NP, Wu J, Estall JL, and Irving BA, et al. (2012) A PGC-1α isoform induced by resistance training regulates skeletal muscle hypertrophy. Cell 151:1319-1331.
28. Ryall JG, Sillence MN, and Lynch GS (2006) Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. Br J Pharmacol 147:587-595.
29. Sacheck JM, Hyatt JP, Raffaello A, Jagoe RT, Roy RR, Edgerton VR, Lecker SH, and Goldberg AL (2007) Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J 21:140-155.
30. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, and Goldberg AL (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117:399-412.
31. Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, Goldberg AL, and Spiegelman BM (2006) PGC-1alpha protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci USA 103:16260-16265.
32. 2-adrenergic receptor expression to muscle hypertrophy and atrophy. J Biomed Biotechnol 2011:729598.
33. Schakman O, Kalista S, Barbé C, Loumaye A, and Thissen JP (2013) Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol 45:2163-2172.
34. Schiaffino S, Dyar KA, Ciciliot S, Blaauw B, and Sandri M (2013) Mechanisms regulating skeletal muscle growth and atrophy. FEBS J 280:4294-4314.
35. Schreiber SN, Emter R, Hock MB, Knutti D, Cardenas J, Podvinec M, Oakeley EJ, and Kralli A (2004) The estrogen-related receptor alpha (ERRalpha) functions in PPARgamma coactivator 1alpha (PGC-1alpha)-induced mitochondrial biogenesis. Proc Natl Acad Sci USA 101:6472-6477.
36. Senf SM, Dodd SL, and Judge AR (2010) FOXO signaling is required for disuse muscle atrophy and is directly regulated by Hsp70. Am J Physiol Cell Physiol 298:C38-C45.
37. Slee AD (2012) Exploring metabolic dysfunction in chronic kidney disease. Nutr Metab (Lond) 9:36.
38. Soppa GK, Smolenski RT, Latif N, Yuen AH, Malik A, Karbowska J, Kochan Z, Terracciano CM, and Yacoub MH (2005) Effects of chronic administration of clenbuterol on function and metabolism of adult rat cardiac muscle. Am J Physiol Heart Circ Physiol 288:H1468-H1476.
39. Springer JP, Kropp BP, and Thor KB (1994) Facilitatory and inhibitory effects of selective norepinephrine reuptake inhibitors on hypogastric nerve-evoked urethral contractions in the cat: a prominent role of urethral beta-adrenergic receptors. J Urol 152:515-519.
40. Wada S, Kato Y, Okutsu M, Miyaki S, Suzuki K, Yan Z, Schiaffino S, Asahara H, Ushida T, and Akimoto T (2011) Translational suppression of atrophic regulators by microRNA-23a integrates resistance to skeletal muscle atrophy. J Biol Chem 286:38456-38465.
41. Wang H, Kubica N, Ellisen LW, Jefferson LS, and Kimball SR (2006) Dexamethasone represses signaling through the mammalian target of rapamycin in muscle cells by enhancing expression of REDD1. J Biol Chem 281:39128-39134.
42. Wills LP, Trager RE, Beeson GC, Lindsey CC, Peterson YK, Beeson CC, and Schnellmann RG (2012) The β2-adrenoceptor agonist formoterol stimulates mitochondrial biogenesis. J Pharmacol Exp Ther 342:106-118.
43. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, and Scarpulla RC, et al. (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98:115-124.